ArticleBMC ophthalmology2025
Evaluation of ganglion cell complex in patients taking hydroxychloroquine.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the ganglion cell complex thickness in patients taking oral hydroxychloroquine.
methodsIn this hospital-based, cross-sectional, non-interventional, comparative study, 87 eyes of 87 patients taking hydroxychloroquine were recruited. All the patients underwent complete ophthalmological evaluation along with dilated fundus examination. Patients were divided into two groups based on the duration of hydroxychloroquine intake: Group 1 (62 patients having duration of hydroxychloroquine intake < 5 years) and Group 2 (25 patients having duration of hydroxychloroquine intake ≥ 5 years). Age and gender-matched healthy volunteers with normal ocular findings were taken as controls. Average, superior, inferior GCC thickness, focal loss volume, and global loss volume were measured by RTvue XR Avanti SD-OCT.
resultsThe average, superior, and inferior GCC thicknesses were significantly reduced in both Group 1 (< 5 years) and Group 2 (≥ 5 years) as compared to controls (p < 0.001). In Group 1, mean GCC values were 94.70 ± 6.34 μm (average), 94.43 ± 6.28 μm (superior), and 94.74 ± 6.81 μm (inferior), while the corresponding values in controls were 99.79 ± 4.61 μm, 99.38 ± 4.63 μm, and 99.97 ± 4.61 μm. Likewise, FLV and GLV in Group 1 were 1.76 ± 2.5% and 4.07 ± 3.27%, significantly higher than in controls (0.72 ± 0.45% and 1.39 ± 1.1%, respectively; p = 0.002 for FLV, p = 0.001 for GLV). Similarly, in Group 2, mean GCC thicknesses were 92.70 ± 6.39 μm (average), 92.44 ± 5.92 μm (superior), and 93.32 ± 7.25 μm (inferior), all significantly lower than in controls (p < 0.001). While GLV was significantly elevated in Group 2 (4.46 ± 4.42%; p-0.003), the difference in FLV (1.23 ± 1.12%) was not statistically significant compared to controls (p-0.077).
conclusionThe Ganglion Cell Complex thickness was significantly thinner in patients taking hydroxychloroquine along with elevated Focal Loss Volume % and Global Loss Volume %. However, no statistically significant correlation was observed between GCC thickness and duration of hydroxychloroquine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.